Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities

ConclusionsThe use of regorafenib may not be suitable in patients with a lowCtrough value. To prevent skin toxicities, theCtrough value of M5 should be monitored.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research